In the version of this article initially published, on p. 958, right-hand column, line 2, it was incorrectly stated that Rituxan is used for treating multiple sclerosis: "Rituxan (rituximab), a B cell-depleting biologic for treating rheumatoid arthritis and multiple sclerosis, has shifted the focus towards B cells." The sentence should have read, "Rituxan (rituximab), a B cell-depleting biologic for treating rheumatoid arthritis and non-Hodgkin's lymphoma, has shifted the focus towards B cells." The error has been corrected in the HTML and PDF versions of the article. e r r ata
